The Patient Partnership Index 2021 is a ground-breaking initiative from leading industry publication PharmaTimes magazine and specialist health communications agency OVID Health.

The inaugural Patient Partnership Index was launched in May 2020, offering pharmaceutical and biotech companies an opportunity to showcase, benchmark and evaluate the quality of their communications and advocacy with patient groups.

Following the tremendous response from industry and patient organisations, the Index is returning in 2021. The aim is to celebrate as many companies that meet the mark, so we can continue to raise the bar across the industry. There are no costs involved – entering the Index is completely free for everyone.

The Index will evaluate the highest standards, based on best practice, of partnerships in communications and advocacy between pharmaceutical, biotech and patient communities.

Companies are offered the opportunity to submit entries to the Index. In return, they will be recognised amongst their industry peers and patient organisations, as well as receive an exclusive insights report from OVID Health. You can pre-register your company to enter in 2021 using the form here.

“Having a Patient Partnership Index, developed with patient groups and judged independently, can keep us moving forwards, sharing best practice and providing a valuable steer on what works best”

Ben Osborn, Pfizer UK country manager

All entrants will have the opportunity to profile their involvement with the Index through their own external and internal channels, and awards for GOLD, SILVER and FINALIST standard entries will be announced by OVID Health to celebrate those companies who both demonstrate and lead best practice in patient partnerships.

“We work hard to build trusted, transparent and lasting relationships with patient organisations, no matter how big or small, to help us understand what matters most to patients and their families……we value platforms such as the Patient Partnership Index which enable us to share our initiatives and learn of other important programmes helping to meet the needs of UK patients.”

Gaetan leblay, managing Director of janssen UK & Ireland